Endometrioid Carcinoma Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
Conditions: Ovarian Clear Cell Adenocarcinoma; Platinum-Sensitive Ovarian Carcinoma; Recurrent Endometrial Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Fallopian Tube Endometrioid Adenocarcinoma; Recurrent Fallopian Tube Serous Adenocarcinoma; Recurre nt Ovarian Carcinoma; Recurrent Ovarian Clear Cell Adenocarcinoma; Recurrent Ovarian Endometrioid Adenocarcinoma; Recurrent Ovarian Serous Adenocarcinoma; Recurrent Platinum-Resistant Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Primary Per itoneal Clear Cel...
Source: ClinicalTrials.gov - February 9, 2022 Category: Research Source Type: clinical trials

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents
Conditions: Fallopian Tube Mucinous Adenocarcinoma; Ovarian Seromucinous Carcinoma; Recurrent Fallopian Tube Clear Cell Adenocarcinoma; Recurrent Fallopian Tube Endometrioid Adenocarcinoma; Recurrent Fallopian Tube Transitional Cell Carcinoma; Recurrent Fallopian Tube Undifferentiated Ca rcinoma; Recurrent High Grade Fallopian Tube Serous Adenocarcinoma; Recurrent High Grade Ovarian Serous Adenocarcinoma; Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma; Recurrent Low Grade Ovarian Serous Adenocarcinoma; Recurrent Ovarian Clear Cell Adenocarcinoma; Recurrent Ovaria...
Source: ClinicalTrials.gov - February 5, 2021 Category: Research Source Type: clinical trials